What's Next for Pfizer After the Company Pulls Its Weight Loss Drug?

The anti-obesity drug market has the potential to be massive, with multiple analysts projecting it may reach at least $100 billion by 2030. As a result, many top healthcare companies are vying for a piece of the market, as doing so could generate significant revenue and profit growth.Pfizer (NYSE: PFE) has been one of those companies, with danuglipron being a treatment it was hopeful could eventually come to market as a once-daily pill. Unfortunately, those hopes recently came to an end.Last week, Pfizer announced that it would no longer develop danuglipron, a daily GLP-1 weight-loss drug which investors were excited about as a potential blockbuster for the company. This wasn't due to a lack of effectiveness, but because a patient in the trial appeared to have elevated liver enzymes -- a sign of possible damage to cells.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool